Communications Biology (Jun 2022)
TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress
- Hiroyuki Ueno,
- Takuya Hoshino,
- Wakako Yano,
- Sayaka Tsukioka,
- Takamasa Suzuki,
- Shoki Hara,
- Yoshio Ogino,
- Khoon Tee Chong,
- Tatsuya Suzuki,
- Shingo Tsuji,
- Hikaru Itadani,
- Ikuo Yamamiya,
- Yoshihiro Otsu,
- Satoshi Ito,
- Toshiya Yonekura,
- Miki Terasaka,
- Nozomu Tanaka,
- Seiji Miyahara
Affiliations
- Hiroyuki Ueno
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba
- Takuya Hoshino
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba
- Wakako Yano
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba
- Sayaka Tsukioka
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba
- Takamasa Suzuki
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba
- Shoki Hara
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba
- Yoshio Ogino
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba
- Khoon Tee Chong
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba
- Tatsuya Suzuki
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba
- Shingo Tsuji
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba
- Hikaru Itadani
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba
- Ikuo Yamamiya
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba
- Yoshihiro Otsu
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba
- Satoshi Ito
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba
- Toshiya Yonekura
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba
- Miki Terasaka
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba
- Nozomu Tanaka
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba
- Seiji Miyahara
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba
- DOI
- https://doi.org/10.1038/s42003-022-03516-4
- Journal volume & issue
-
Vol. 5,
no. 1
pp. 1 – 12
Abstract
A small-molecule protein-protein interaction inhibitor of ribonucleotide reductase subunit, TAS1553, is shown to inhibit growth of both hematological and solid cancer xenograft tumors following oral administration in mice.
